- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03466112
Aerobic Exercise for the Improvement of Cognition and Enhancement of Recovery in Post-acute Schizophrenia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Bavaria
-
Munich, Bavaria, Germany, 80366
- Ludwig-Maximilians-University of Munich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent given by the subject; DSM-IV-TR diagnosis of schizophrenic psychosis (295.10-30, 295.90); age 18 to 65 years, male or female; PANSS at baseline: total score ≤ 75, proper contraception in female patients of childbearing potential; treatment with one or two antipsychotics in a stable dose of at least two weeks, body mass index between 18 and 40.
Exclusion Criteria:
- Lack of accountability; positive urine drug-screening for illicit drugs at screening (except benzodiazepines); serious suicidal risk at screening visit; other relevant interferences of axis 1 according to diagnostic evaluation (MINI); other relevant neurological or other medical disorders; pregnancy or lactation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: endurance training
endurance training with stationary bicycles
|
endurance training with stationary bicycles
Other Names:
|
Active Comparator: balance and tone program
flexibility, core strength, balance, relaxation
|
flexibility, core strength, balance, relaxation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
all-cause discontinuation
Time Frame: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
|
Reason of study discontinuation will be identified.
The all-cause-discontinuation questionnaire will be called up 9 times from baseline up to 12 months (compare time frame) including 26 weeks of intervention and 26 weeks follow up period.
Reasons are defined as (1) relevant worsening of clinical symptoms (PANSS total score above 75 on cancerous visits for more than 14 days.
(2) failure to take the prescribed medication for more than 14 days.
(3) Failure to comply scheduled study or diagnostic appointments for more than 6 weeks (4) Patient unavailability despite extensive efforts of the treatment team (5) Withdrawal of patient consent (6) Clinician discontinuation.
|
12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
improvement in neurocognition (VLMT)
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Verbal Learning and Memory Test (VLMT).
|
12 months (at baseline, day 98, day 182 and day 365)
|
improvement in neurocognition (DSST)
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using a test of verbal declarative episodic memory, the Digit Symbol Substitution Test (DSST).
|
12 months (at baseline, day 98, day 182 and day 365)
|
improvement in neurocognition (TMT)
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Trail Making Test A and B (TMT) as a test of executive functions, quick visual comprehension, attention, and processing speed.
|
12 months (at baseline, day 98, day 182 and day 365)
|
improvement in neurocognition (B-CATS)
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
The partial aspect of verbal fluid from the letter Cognitive Assessment Tool for Schizophrenia (B-CATS) is also used in the neuropsychological investigation at the main measurement times (at baseline, day 98, day 182 and day 365).
|
12 months (at baseline, day 98, day 182 and day 365)
|
improvement in neurocognition (MASC)
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Facial Affect Recognition (AOP) and Theory of Mind methods.
These are tasks using the Movie for the Assessment of Social Cognition (MASC).
|
12 months (at baseline, day 98, day 182 and day 365)
|
improvement in psychopathology (PANSS)
Time Frame: 12 months (At baseline, day 98, 182 and day 365)
|
The assessment of psychopathology on the basis of a patient interview takes place at all main measurement times.
At baseline, day 98, 182 and day 365.
The PANSS uses a standard procedure for assessing schizophrenia symptoms, which measures the severity of individual symptoms as well as the various symptom subgroups of positive and negative symptoms and general psychopathology.
|
12 months (At baseline, day 98, 182 and day 365)
|
improvement in psychopathology (CGI)
Time Frame: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
|
The Clinical Global Impression Scale (CGI) assesses the overall symptom severity and response to interventions or therapies for psychiatric conditions to assess the effectiveness of the measures applied.
It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.
|
12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
|
improvement in psychopathology (SOFAS)
Time Frame: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
|
The Social and Occupational Functioning Assessment Scale (SOFAS) estimates social and professional performance.
It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.
|
12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
|
improvement in psychopathology (GAF)
Time Frame: 12 months (At baseline, day 98, 182 and day 365)
|
The Social Assessment of Functioning Scale (GAF) also estimates social and professional performance.
It takes place at all main measurement times.
At baseline, day 98, 182 and day 365.
|
12 months (At baseline, day 98, 182 and day 365)
|
improvement in psychopathology (BSI-53)
Time Frame: 12 months (At baseline, day 98, 182 and day 365)
|
The Brief Symptom Inventory (BSI-53) records the symptoms using 53 items.
It takes place at all main measurement times.
At baseline, day 98, 182 and day 365.
|
12 months (At baseline, day 98, 182 and day 365)
|
improvement in psychopathology (CDSS)
Time Frame: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
|
The Calgary Depression Scale for Schizophrenia (CDSS) measures suicidality and severity of depressive symptoms.
It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.
|
12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
|
improvement in social and occupational functioning (UPSA-B)
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
The University of California San Diego Performance-based Skills Assessment (UPSA-B) will be used to assess the day-to-day functioning of patients with schizophrenia in the household, communications, finance, transportation, and leisure activities role play situations.
It takes place at all main measurement times.
At baseline, day 98, 182 and day 365.
|
12 months (at baseline, day 98, day 182 and day 365)
|
improvement in social and occupational functioning (FROGS)
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
Functional Remission of General Schizophrenia (FROGS) is used as a tool to measure changes in functional levels.
It takes place at all main measurement times.
At baseline, day 98, 182 and day 365.
|
12 months (at baseline, day 98, day 182 and day 365)
|
improvement in social and occupational functioning (PSP)
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
The Personal and Social Performance Scale (PSP) is also a tool to measure changes in functional levels.
It takes place at all main measurement times.
At baseline, day 98, 182 and day 365.
|
12 months (at baseline, day 98, day 182 and day 365)
|
improvement in quality of life
Time Frame: 12 months (at baseline, day 182 and day 365)
|
Only at the beginning and end of the intervention, and after one year, is the World Health Organization's Quality of Life Questionnaire (WHOQOL-Bref) used to record quality of life (The WHOQOL Group, 1998).
|
12 months (at baseline, day 182 and day 365)
|
improvement in body mass index (BMI)
Time Frame: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
|
Also, the body height (in meter) and weight (in kg) of the study participants are measured.
Thereupon the BMI is calculated from the body weight (kg) divided by the square of the height (m2).
The unit of BMI is kg / m2.
|
12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
|
change of connectivity analysis (MRI of the brain)
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
At four time points, just prior to initiation of V1, V4, V6 after the end of the intervention and at V9 after the follow-up period of 6 months, structural and functional MRI (fMRI) examinations are performed on a 3 Tesla whole-body MR scanner in patients and healthy control subjects (Siemens) made. The findings are compared with data from healthy controls and non-diseased first-degree relatives of patients with schizophrenia who have been evaluated in other BMBF-funded studies ("MooDS", "IntegraMent"). In addition, cross-sectional comparisons (TAU + Exercise vs. TAU + BKGT) and progress measurements to characterize treatment effects are planned. The measurements are divided into 2 appointments to reduce the burden on patients and subjects by the measurement time. |
12 months (at baseline, day 98, day 182 and day 365)
|
change of volumes of brain regions (MRI)
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
First, structural measurements (T1 sequence, duration: approx.
5 minutes) and investigations of the fiber connections in the brain by means of diffusion-weighted imaging (DTI, duration: approx.
10 minutes) are carried out.
|
12 months (at baseline, day 98, day 182 and day 365)
|
change of brain function (MRI)
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
By means of fMRI, the tasks resting activity, working memory, episodic memory, reward processing, social perspective takeover, emotion processing as well as ability to inhibit are to be investigated with already well pre-examined tasks. A function measurement is performed at rest without stimulation (rsMRT), which provides information on the functional networking of different brain regions at rest (duration: approx. 5 minutes). There are also three fMRI surveys that record brain activity during simple psychological tasks. - The ability to inhibit (prefrontal cortex, anterior cingulate gyrus) is examined by means of a so-called flanker task. This is to respond to a specific target stimulus, which is surrounded by either the same (congruent) or by distracting (incongruent) stimuli. - Duration: 11 minutes |
12 months (at baseline, day 98, day 182 and day 365)
|
improvement of endurance capacity
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
As part of the sports medical stress test, the determination of endurance performance in patients and control subjects takes place. For this examination, like in training, finder bike use and measurements of heart rate, lactate concentration and exertion sensation are performed. The ergometry is carried out as a Vita maxima examination, so it ends when the subjects can not or do not want to keep pedaling or when the termination criteria according to Steinacker & Liu (2002) occur. From the examination, various submaximal and maximal parameters can be determined, have the validity for endurance performance and the training intensity can be determined. The examination is carried out under standardized and safe conditions and after a detailed medical history and physical examination to exclude contraindications. Activity meters are used to control the physical activity of study participants outside the study intervention. |
12 months (at baseline, day 98, day 182 and day 365)
|
change of medication and attitude of the study participants to therapy (DAI)
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
Also, the attitude of the study participants to therapy and medication is recorded.
For this, the Drug Attitude Inventory (DAI) is used.
Is takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
|
12 months (at baseline, day 98, day 182 and day 365)
|
change of medication and attitude of the study participants to therapy (SES)
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
The Service Engagement Scale (SES), which assesses accessibility, cooperation, help seeking and adherence, is used.
It takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
|
12 months (at baseline, day 98, day 182 and day 365)
|
improvement in metabolic parameters
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
The laboratory diagnostic measures include a laboratory blood test, with evaluation of blood lipid levels, the C-reactive protein, glycohemoglobin (HBA1c).
It takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
|
12 months (at baseline, day 98, day 182 and day 365)
|
urine (testing pregnancy and drug abuse)
Time Frame: baseline
|
Examination of the urine at baseline excludes pregnancy and drug abuse.
|
baseline
|
gene expression
Time Frame: baseline
|
Investigation of gene expression takes place at baseline.
|
baseline
|
change of genome-wide epigenetics
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
Investigation of genome-wide epigenetics takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
|
12 months (at baseline, day 98, day 182 and day 365)
|
change of proteomics
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
Investigation of proteomics at the main measurement times (at baseline, day 98, day 182 and day 365).
|
12 months (at baseline, day 98, day 182 and day 365)
|
change of BDNF level
Time Frame: 12 months (at baseline, day 98, day 182 and day 365)
|
Investigation of BDNF levels at the main measurement times (at baseline, day 98, day 182 and day 365).
|
12 months (at baseline, day 98, day 182 and day 365)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Peter G. Falkai, Prof. Dr., LMU Munich
Publications and helpful links
General Publications
- Maurus I, Roell L, Keeser D, Papazov B, Papazova I, Lembeck M, Roeh A, Wagner E, Hirjak D, Malchow B, Ertl-Wagner B, Stoecklein S, Hasan A, Schmitt A, Meyer-Lindenberg A, Falkai P. Fitness is positively associated with hippocampal formation subfield volumes in schizophrenia: a multiparametric magnetic resonance imaging study. Transl Psychiatry. 2022 Sep 16;12(1):388. doi: 10.1038/s41398-022-02155-x.
- Roell L, Maurus I, Keeser D, Karali T, Papazov B, Hasan A, Schmitt A, Papazova I, Lembeck M, Hirjak D, Sykorova E, Thieme CE, Muenz S, Seitz V, Greska D, Campana M, Wagner E, Loehrs L, Stoecklein S, Ertl-Wagner B, Poemsl J, Roeh A, Malchow B, Keller-Varady K, Meyer-Lindenberg A, Falkai P. Association between aerobic fitness and the functional connectome in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2022 Oct;272(7):1253-1272. doi: 10.1007/s00406-022-01411-x. Epub 2022 Apr 30.
- Maurus I, Hasan A, Schmitt A, Roeh A, Keeser D, Malchow B, Schneider-Axmann T, Hellmich M, Schmied S, Lembeck M, Keller-Varady K, Papazova I, Hirjak D, Topor CE, Walter H, Mohnke S, Vogel BO, Wolwer W, Schneider F, Henkel K, Meyer-Lindenberg A, Falkai P. Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial. Eur Arch Psychiatry Clin Neurosci. 2021 Mar;271(2):315-324. doi: 10.1007/s00406-020-01175-2. Epub 2020 Aug 3. Erratum In: Eur Arch Psychiatry Clin Neurosci. 2021 Oct;271(7):1405-1406.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Version (V) 2.0 - 30.07.2018
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on endurance training
-
University of GiessenHannover Medical SchoolUnknownType 2 DiabetesGermany
-
Schön Klinik Berchtesgadener LandCompletedChronic Obstructive Pulmonary DiseaseGermany
-
University Hospital HeidelbergDietmar Hopp Stiftung; Friederike Rosenberger (University Hospital Heidelberg)...Completed
-
Molde University CollegeCompleted
-
University of ViennaCompletedCOVID-19 | Post-COVID-19 Syndrome | Long COVID-19Austria
-
Landsteiner InstitutLund University; Medical University of Vienna; Mein Hanusch-Krankenhaus; Fondazione... and other collaboratorsCompletedType 2 Diabetes Mellitus | Insulin ResistanceAustria
-
Universität des SaarlandesThe German Heart FoundationCompletedChronic Heart Failure | Dilated CardiomyopathyGermany
-
General Committee of Teaching Hospitals and Institutes...Cairo University; Taibah UniversityCompleted
-
University of LiegeCompletedInflammatory Bowel Diseases | Exercise TherapyBelgium
-
University Hospital, BrestUnknown